Envision Pharma Group (Envision) has appointed Dr. Deepti Sodhi Jaggi to the Envision Board of Directors
“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.”
Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.
Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.
Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.
“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi.
Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business.Close
Envision Pharma Group is an exhibitor and elite sponsor at the 2023 European Meeting of ISMPP that is taking place from January 24–25 in London, UK.
The onsite Envision team shares its key takeaways from ISPOR Europe 2022
Envision Pharma Group (Envision) today announced the appointment of two senior executives while further expanding its global focus on M&A, technology-enabled solutions, and strategic consulting for the life sciences industry.
Dominic “Nick” Marasco has joined as Chief Commercial Officer of Envision Pharma Group, and member of the Executive Leadership Team. Nick is an experienced global commercial leader with nearly 30 years of pharmaceutical, biotech, and medical device industry experience. Having held several C-suite positions he has a proven track record of successfully launching and growing products and solutions with a focus on driving profitable revenue growth, building, and leading high-performing commercial organizations.
Nick will lead the development of Envision’s commercial-to-customer strategy while identifying new pathways to progression, with a focus on continuing its revenue growth and expanding its customer reach and solutions. He will help develop, lead, and reinforce Envision’s position as a technology-enabled commercialization, data analytics, and integrated medical capabilities and solutions company. Another key part of his role is to implement a coordinated and integrated sales structure across Envision to reinforce its technology-enabled positioning.
Before joining Envision, Nick served as Chief Commercial Officer of BioAgilytix, supporting three buyer-side acquisitions and integrations, as well as one sell-side sale of BioAgilytix to new private equity owners. Prior to BioAgilytix, he served as Executive Vice President, Global Business Development, Commercial at Syneos Health, where he led the overall strategic direction of the global business development team for the commercial division, both in the US and internationally.
Nick was also previously Head of US Sales for the Neuroscience Business Unit at Amgen, and prior to that Global Commercial Head, Amgen Biosimilars. He has also held executive-level commercial and business development positions at Sandoz Biopharmaceuticals (a Novartis company) and IQVIA (formerly Quintiles).
Nick shares, “It is a distinct pleasure to join both Meg Heim and the entire team at Envision Pharma Group. Envision is a company that is experiencing phenomenal growth and high customer engagement and loyalty across each of the pillars of the organization and has continued to realize the growing demand of customer needs and advisory services. Even better, Envision has excelled at progressive innovation via services and technology to achieve a comprehensive solutions-oriented service platform. I am excited to join this dynamic team.”
Gregory “Greg” Carpenter joins Envision Pharma Group as Chief of Staff, CEO, and member of the Executive Leadership Team and brings with him a wealth of global experience and expertise.
Greg has held several leadership roles in the pharmaceutical industry and positions spanning sales, marketing, medical, and transformation. His expertise covers areas of communications, strategic planning and implementation, coalition and consensus-building leadership development, omnichannel marketing, and change management.
Before joining Envision, Greg’s most recent role was leading a go-to-market transformation for the Sanofi US General Medicines team that included building an enterprise artificial intelligence (AI) solution, and helping the organization understand and embrace omnichannel marketing.
Greg says, “I am delighted to join Envision Pharma Group and help carry out our mission of improving lives through a compelling combination of technology and services to enable clients to better serve patients. Through our expertise in scientific and commercialization strategy and solutions, medical affairs, and AI-driven technology solutions, Envision is helping our customers to excel in a rapidly changing healthcare environment.”
Meg Heim, Chief Executive Officer of Envision Pharma Group, adds, “I am so excited to welcome Nick and Greg to the Envision team. These new positions are critical to the fulfilment of our business expansion, mission, as well as being a commitment to our vision that enables us to execute upon our strategic plans.”Close
Envision Pharma Group is an exhibitor and elite sponsor at the 2023 European Meeting of ISMPP that is taking place from January 24–25 in London, UK.
Meet the Envision team (Dawn Lobban, Catherine Elliot, Lizzie Perdeaux, Hiroko Ebina, Andy Shepherd, Lauren Manning, Stephen Craig, and Leif Måsvær) at booth #9 to discover how we connect our world-leading technology solutions with powerful scientific communications, driven by improving patient outcomes everywhere. At our booth, you can contribute your own scribe illustration in support of the ISMPP meeting theme “fueling creativity”!
For a demonstration of how our technology solutions simplify collaborative reviews for research through services such as iEnvision® and doDOC®, or to find out more about our services – request a meeting with the on-site team at MeetMe@envisionpharma.com.
We will be providing updates before, during, and after the event and will be sharing these through our social media page and this event web page, so check back soon. For the “What's on at ISMPP EU 2023” information, click the button below.Close
The Envision Value & Access team shares key takeaways from the ISPOR EU meeting in Vienna earlier this month. You can access the report below.
For more information on how we can support your value and access strategy and communications in an evolving world, contact the team at: firstname.lastname@example.org
Envision Value & Access unites market access strategy and scientific communications expertise. Collaboration and partnership are at the core of our philosophy, bringing together experts from across Envision Pharma Group, patient collaborators, and client partners to support access to innovative health technologies.
Leading global technology-enabled scientific communications company Envision Pharma Group is a platinum sponsor at ISPOR EU 2022, as well as an exhibitor.
Any new drug launch must overcome numerous obstacles in the pursuit of success
“Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc.” So how does this differ for a small and emerging biotech firm?”
In an article published earlier this year, Envision Pharma Group’s Rachel Shemer, along with Two Labs Angus Bromley and Kimberly Cash, discuss the advantages and challenges smaller companies face.Close
“To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy, and care over recent years, it is of crucial importance to ensure all patients with cancer have a role and an ongoing dialogue with the healthcare team.”
Ensuring all patients with cancer have a role and an ongoing dialogue with their healthcare team is crucial.
In a whitepaper published earlier this year Envision Pharma Group’s Rebecca Goldstein, PhD, CMPP, and 90TEN’s Mark Lakeram discuss the value of diverse patient representation and engagement in cancer treatment.Close
Envision Value & Access is an exhibitor and platinum sponsor at ISPOR EU 2022. As an insight-driven strategic consulting partner for clients and with a full array of HEOR and access services, from the development of your HEOR strategy and RWE roadmap through to evidence generation and communication, we work across functions to develop, communicate, and capture the value of products through a coherent and integrated payer strategy to improve patient access and outcomes globally.
Come meet Suki Kandola, Joe Merkert, and other Envision Value & Access team members at ISPOR Europe 2022, Booth X2-210!
November 6-9; Vienna, Austria
Want to meet at a specific day and time at the event? Then send a message to: Value@envisionpharma.com
Envision Value & Access has the following posters presented at ISPOR Europe 2022:
Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.
Meg Heim named as its new Chief Executive Officer
Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.
Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.
Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”
Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”Close
Envision Pharma Group is pleased to announce the appointment of Meg Heim as its new Chief Executive Officer. Meg is an accomplished business leader with strong leadership experience, and an established reputation within Pharmaceutical, Medical Device and Health Technology markets. Throughout her career she has championed the professionalism of medical affairs and the innovations that improve patient experience.
Working closely with a strong and experienced Executive Leadership Team, Meg will be responsible for delivering an ambitious five-year plan that will reinforce Envision as the global leader in scientific and commercialization strategy and solutions; medical affairs; and lifecycle planning enabled by leading technology solutions and world-class people.
Meg joins Envision at a pivotal moment, with Group performance accelerating as it continues to deliver a compelling combination of technology and services to clients. Envision’s strategy and innovation has ensured the company continues to serve and anticipate its clients’ evolving needs. Meg replaces David Thompson, who steps down as CEO to pursue other opportunities, including in the not-for-profit sector at a cancer charity, after more than six years with Envision Pharma Group and over 25 years in the industry.
Brian Hepburn Executive Co-Chair of Envision Pharma Group said: “I am truly excited by the appointment of Meg as our new Chief Executive Officer. Meg has an established track record within the healthcare industry and brings with her a deep understanding of medical affairs which will be highly complementary to the existing expertise within the business. This is an exciting time for Envision as we continue to accelerate innovation and work towards our vision of improving lives through the power of our technology and expertise.”
Meg said: “I am energized to be joining Envision Pharma Group at such an important time in the industry. I see a clear opportunity for further growth building off established and new opportunities in the sector. The company has an exceptional team and client base, and I am looking forward to spending time with our people, our clients, and other key partners.”
Following the announcement in March of our Vitaccess partnership that is designed to power evidence generation for the biopharmaceutical industry, we are thrilled to be collaborating with Vitaccess on its “Keeping it real” webinar series.
On July 20, Envision’s Dawn Lobban, Global Lead, Patient Partnerships from Envision the Patient, will join Dr. Catherine Bottomley, Chief Scientific Officer from Vitaccess, to discuss patient engagement in the publication of real-world evidence (RWE). Secure your seat here in order to listen to two engaging and passionate speakers cover patient engagement and RWE.Close
Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules
Move combines Envision’s global leadership position in medical affairs communications with Vitaccess’ award-winning capabilities in real-world evidence (RWE)
Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) today announced Library, Datavision, and Scientific Communication Platform (SCP) modules will now feature Smart Citations from scite, an award-winning tool that helps students and researchers discover and understand research findings better.
Fully integrated into the publication details held within Library, Datavision, and SCP modules, Smart Citation badges provide regularly updated, at-a-glance views of how research has been cited and permits click-through access to the scite website for more detailed information on the article. This new functionality sits alongside and enhances the existing article-level metrics provided in iEnvision through integrations with Altmetric and Scopus.
Russell Traynor, Envision’s Global Head, iEnvision Platform Strategy, and former chair of the International Society of Medical Publication Professionals, said, “We are excited to announce this collaboration and hope that the addition of Smart Citations to Library, Datavision, and SCP will provide additional insights and value to the users of our solutions.”
Dr. Josh Nicholson, Chief Executive Officer of scite, added, “We’re very happy to be working with Envision to provide a powerful integration between the two platforms. Smart Citations are already used by various pharmaceutical companies and communications agencies and we’re happy to surface them in Library for a more streamlined workflow.”
Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com
scite is a Brooklyn-based start-up that helps researchers discover and evaluate scientific articles better through Smart Citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from around the world and is funded in part by the National Science Foundation and the National Institute of Drug Abuse of the National Institutes of Health. Learn more at: scite.ai
Library, built on the iEnvision medical project management platform, serves as a central repository for the enterprise-wide storage and sharing of final, approved scientific and medical materials such as publications and slide decks. Embedding Smart Citation in Library allows an at-a-glance view of the total number of times a paper has been cited and the context of these citations. Learn more at: www.envisionpharmagroup.com/technology/ienvision-library
The iEnvision Datavision module is designed to drive the compliant and efficient management of scientific and medical publications. With role-specific dashboards, publication managers can access the detailed information needed to start and manage publications. Containing built-in checklists and system validation, it ensures publications comply with Good Publication Practice and the International Committee of Medical Journal Editors (ICMJE) requirements. Learn more at: www.envisionpharmagroup.com/technology/datavision
iEnvision’s SCP is a centralized medical affairs solution, linking key scientific themes and statements to product-related assets such as publications, slides, and videos. The common template of SCP themes, key statements, and supporting statements maintains simple user navigation and a standardized approach to the formatting and development of SCPs – with a lexicon designed to ensure a consistent use of language that includes preferred and prohibited terms. Learn more at: www.envisionpharmagroup.com/technology/scientific-communication-platform-moduleClose
Leading global technology-enabled scientific communications company Envision Pharma Group has launched a suite of behavioral science-led solutions to expand the group’s capabilities and optimize value offering to its clients.
Envision the Change is spearheaded by Mark Lakeram (Global Lead, Behavioral Science) and supported by Directors Jenny Squibbs (in the UK) and Justine Swann (in the US). As a dedicated team of behavioral scientists, they understand that to affect real change the intricacies and realities of everyday life and health need to be considered.
Lakeram said, “All healthcare decisions are influenced by human behavior. By taking into account the science behind this, our proprietary Feel-Think-DoTM model helps to decode why people make the decisions they do. From strategic and tactical planning, to aiding information recall through data visualization and adult learning techniques – we provide counsel and support to drive behavior change that ultimately improves health outcomes.”
Susanne Clark, Head of Envision Scientific Solutions, added, “No matter what product challenges are ahead, understanding the behavior of key stakeholders will be paramount. I’m delighted that we’ve strengthened our service offering with Envision the Change in order to support our clients across all aspects of medical affairs and marketing, from planning to creative implementation for both external and internal audiences.”Close
Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) has announced a partnership with Vitaccess, an innovative research organization.
The Envision and Vitaccess partnership will bring a full-service, customizable approach to data gathering, insight generation, and scientific communications that will stand up to the nuances, scale, and challenges of any client setting.
Acknowledging that every client need is unique, this collaboration will help leverage patient-centric digital solutions to gather data quickly, flexibly, and at scale, and incorporate patients’ “lived experience” – insights which are often insufficiently integrated into the design and implementation of many RWE studies published globally.
The complexities in bringing a product to market cannot be underestimated. An increasing requirement for data leads to a growing need for more adaptive RWE research to be generated and communicated to regulators, pre and post approval. Envision and Vitaccess understand these additional demands placed on their biopharma clients, and the need to maximize value and access to their products through timely, insightful evidence generation which communicates the real-world impact of diseases and their treatments on patients.
Paul Archer, Envision Chief Commercial Strategy Officer, said, “This collaboration offers clients a really powerful toolbox to accelerate, scale, and publish their evidence-generation activities. We admire Vitaccess’ innovative, inclusive digital approach to designing patient-centric RWE studies, and whose flexible solutions provide access to outcomes measures that serve regulators, payers, and health systems all over the world.”
Dr. Mark Larkin, CEO and Founder of Vitaccess, commented, “Combining our Vitaccess Real™ real-time RWE platform and expertise in patient-centric research with Envision’s established leadership in medical affairs and communications brings clients a unique, full-service offering for engaging with patients and caregivers globally.”Close